

# Panos Kanavos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2163873/publications.pdf>

Version: 2024-02-01

110  
papers

4,022  
citations

117625

34  
h-index

138484

58  
g-index

112  
all docs

112  
docs citations

112  
times ranked

4098  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the economic challenges posed by orphan drugs. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 36-42.	0.5	214
2	Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. <i>Health Policy</i> , 2015, 119, 964-979.	3.0	200
3	Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. <i>European Journal of Health Economics</i> , 2018, 19, 123-152.	2.8	198
4	Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom. <i>Health Affairs</i> , 2006, 25, 337-347.	5.2	183
5	Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. <i>Social Science and Medicine</i> , 2017, 188, 137-156.	3.8	135
6	Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. <i>Social Science and Medicine</i> , 2015, 124, 39-47.	3.8	126
7	Encouraging the use of generic medicines: implications for transition economies. <i>Croatian Medical Journal</i> , 2002, 43, 462-9.	0.7	112
8	PARS PLANA VITRECTOMY FOR VITREOMACULAR TRACTION SYNDROME. <i>Retina</i> , 2013, 33, 2012-2017.	1.7	94
9	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017, 35, 1271-1285.	3.3	94
10	Competition in off-patent drug markets: Issues, regulation and evidence. <i>Economic Policy</i> , 2008, 23, 499-544.	2.3	92
11	Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?. <i>Health Affairs</i> , 2003, 22, 16-30.	5.2	91
12	Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. <i>Health Affairs</i> , 2013, 32, 753-761.	5.2	82
13	SYMPTOMATIC VITREOMACULAR ADHESION. <i>Retina</i> , 2013, 33, 1503-1511.	1.7	81
14	Do generics offer significant savings to the UK National Health Service?. <i>Current Medical Research and Opinion</i> , 2007, 23, 105-116.	1.9	74
15	Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions. <i>Health Policy</i> , 2012, 108, 167-177.	3.0	72
16	Medical technology procurement in Europe: A cross-country comparison of current practice and policy. <i>Health Policy</i> , 2011, 100, 43-50.	3.0	70
17	VITREOUS ATTACHMENT IN AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA, AND RETINAL VEIN OCCLUSION. <i>Retina</i> , 2013, 33, 1099-1108.	1.7	65
18	Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment. <i>Pharmacoeconomics</i> , 2016, 34, 435-446.	3.3	65

#	ARTICLE	IF	CITATIONS
19	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	2.8	59
20	PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA. <i>Retina</i> , 2017, 37, 886-895.	1.7	58
21	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	2.8	53
22	Determinants of branded prescription medicine prices in OECD countries. <i>Health Economics, Policy and Law</i> , 2011, 6, 337-367.	1.8	52
23	Health care inequities in north India: role of public sector in universalizing health care. <i>Indian Journal of Medical Research</i> , 2012, 136, 421-31.	1.0	51
24	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	2.8	50
25	The dynamics of colorectal cancer management in 17 countries. <i>European Journal of Health Economics</i> , 2010, 10, 115-129.	2.8	48
26	Resource Allocation and Priority Setting in Health Care: A Multi-criteria Decision Analysis Problem of Value?. <i>Global Policy</i> , 2017, 8, 76-83.	1.7	47
27	Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. <i>Global Policy</i> , 2017, 8, 84-92.	1.7	46
28	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. <i>European Journal of Health Economics</i> , 2019, 20, 891-918.	2.8	45
29	RESPONSIVENESS OF THE EQ-5D TO CLINICAL CHANGE: IS THE PATIENT EXPERIENCE ADEQUATELY REPRESENTED?. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 10-19.	0.5	44
30	Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. <i>BMC Health Services Research</i> , 2015, 15, 428.	2.2	42
31	Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. <i>Health Policy</i> , 2019, 123, 159-165.	3.0	42
32	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	2.8	41
33	Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study. <i>Health Policy</i> , 2016, 120, 35-45.	3.0	39
34	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> , 2012, 108, 19-26.	3.0	38
35	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	2.8	38
36	What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward. <i>Value in Health</i> , 2012, 15, 1182-1184.	0.3	37

#	ARTICLE	IF	CITATIONS
37	Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain. <i>Health Policy</i> , 2010, 95, 245-254.	3.0	36
38	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 43-52.	2.8	35
39	CAN ECONOMIC EVALUATION GUIDELINES IMPROVE EFFICIENCY IN RESOURCE ALLOCATION? The Cases of Portugal, the Netherlands, Finland, and the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , 2000, 16, 1179-1192.	0.5	34
40	International Comparisons of Health Care Expenditures: What We Know and What We Do not Know. <i>Journal of Health Services Research and Policy</i> , 1999, 4, 122-126.	1.7	33
41	Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States. <i>Health Policy</i> , 2014, 118, 229-241.	3.0	33
42	Does external reference pricing deliver what it promises? Evidence on its impact at national level. <i>European Journal of Health Economics</i> , 2020, 21, 129-151.	2.8	33
43	The generics paradox revisited: empirical evidence from regulated markets. <i>Applied Economics</i> , 2013, 45, 3230-3239.	2.2	32
44	Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?. <i>Current Medical Research and Opinion</i> , 2007, 23, 2467-2476.	1.9	30
45	SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 218-232.	0.5	30
46	Health economics: an evolving paradigm. , 2000, 9, 183-190.		29
47	Implications of external price referencing of pharmaceuticals in Middle East countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 993-998.	1.4	29
48	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	2.8	28
49	Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. <i>Health Policy</i> , 1997, 41, 241-260.	3.0	26
50	Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. <i>Globalization and Health</i> , 2009, 5, 19.	4.9	26
51	Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries. <i>Value in Health</i> , 2017, 20, 919-926.	0.3	26
52	Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. <i>Future Oncology</i> , 2018, 14, 1701-1710.	2.4	26
53	Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 137-142.	2.8	25
54	The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. <i>Health Economics Review</i> , 2011, 1, 18.	2.0	25

#	ARTICLE	IF	CITATIONS
55	User charges in health care: evidence of effect on service utilization & equity from north India. Indian Journal of Medical Research, 2012, 136, 868-76.	1.0	24
56	Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskeletal Disorders, 2016, 17, 321.	1.9	23
57	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	3.0	23
58	The economics of blood: Gift of life or a commodity?. International Journal of Technology Assessment in Health Care, 2006, 22, 338-343.	0.5	22
59	Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries. PharmacoEconomics - Open, 2022, 6, 315-328.	1.8	22
60	Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Applied Health Economics and Health Policy, 2022, 20, 757-768.	2.1	22
61	Outstanding Regulatory Aspects in the European Pharmaceutical Market. PharmacoEconomics, 1999, 15, 519-533.	3.3	20
62	Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia. Applied Economics, 2007, 39, 541-551.	2.2	19
63	Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational New Drugs, 2022, 40, 798-809.	2.6	18
64	An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?. European Journal of Health Economics, 2019, 20, 329-332.	2.8	17
65	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. European Journal of Health Economics, 2016, 17, 67-78.	2.8	16
66	Cross-Border Issues in the Provision of Health Services: Are We Moving towards a European Health Care Policy?. Journal of Health Services Research and Policy, 2000, 5, 231-236.	1.7	15
67	Using IMPRESS to guide policy change in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1251-1255.	3.0	15
68	Product differentiation, competition and regulation of new drugs: the case of statins in four European countries. Managerial and Decision Economics, 2007, 28, 455-465.	2.5	14
69	Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First. Journal of Clinical Oncology, 2016, 34, 2935-2936.	1.6	14
70	DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS. International Journal of Technology Assessment in Health Care, 2018, 34, 498-506.	0.5	14
71	Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America. Health Policy and Planning, 2021, 36, 790-810.	2.7	14
72	Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey. Applied Health Economics and Health Policy, 2013, 11, 639-652.	2.1	13

#	ARTICLE	IF	CITATIONS
73	Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy, 2020, 124, 239-251.	3.0	13
74	ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations. Value in Health, 2020, 23, 1040-1048.	0.3	13
75	The Single Market for Pharmaceuticals in the European Union in Light of European Court of Justice Rulings. Pharmacoeconomics, 2000, 18, 523-532.	3.3	11
76	Competition in prescription drug markets: is parallel trade the answer?. Managerial and Decision Economics, 2010, 31, 325-338.	2.5	11
77	A comparative analysis of coverage decisions for outpatient pharmaceuticals: Evidence from Denmark, Norway and Sweden. Health Policy, 2015, 119, 203-211.	3.0	11
78	Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. Orphanet Journal of Rare Diseases, 2019, 14, 154.	2.7	11
79	Financing pharmaceuticals in transition economies. Croatian Medical Journal, 1999, 40, 244-59.	0.7	10
80	Cross border health care in Europe. BMJ: British Medical Journal, 1999, 318, 1157-1158.	2.3	9
81	Colorectal cancer management in the United Kingdom: current practice and challenges. European Journal of Health Economics, 2010, 10, 85-90.	2.8	9
82	Is the Funding of Public National Health Systems Sustainable over the Long Term? Evidence from Eight OECD Countries. Global Policy, 2017, 8, 7-22.	1.7	9
83	Strategic procurement and international collaboration to improve access to medicines. Bulletin of the World Health Organization, 2017, 95, 720-722.	3.3	9
84	International impact of external reference pricing: should national policy-makers care?. European Journal of Health Economics, 2019, 20, 1147-1164.	2.8	9
85	Variations in external reference pricing implementation: does it matter for public policy?. European Journal of Health Economics, 2019, 20, 1375-1397.	2.8	9
86	Will Managed Care Work in Europe?. Pharmacoeconomics, 1997, 11, 297-305.	3.3	8
87	An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice, 2014, 7, 4.	2.4	8
88	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. Medical Decision Making, 2020, 40, 830-845.	2.4	8
89	Insurance Coverage and the Heterogeneity of Health and Drug Spending in the United States. Geneva Papers on Risk and Insurance: Issues and Practice, 2006, 31, 669-691.	2.1	7
90	Parallel Trade and Pharmaceutical Prices: A Game-theoretic Approach and Empirical Evidence from the European Union. World Economy, 2014, 37, 856-880.	2.5	7

#	ARTICLE	IF	CITATIONS
91	Coloctreral cancer management and prevention policies in Greece. <i>European Journal of Health Economics</i> , 2010, 10, 27-33.	2.8	6
92	Availability of medical supplies during the 2010 Pakistan floods. <i>The Lancet Global Health</i> , 2013, 1, e13-e14.	6.3	6
93	Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. <i>European Journal of Health Economics</i> , 2016, 17, 991-999.	2.8	6
94	Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. <i>Health Policy</i> , 2019, 123, 118-129.	3.0	6
95	Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?. <i>Health Policy</i> , 2020, 124, 1297-1309.	3.0	6
96	Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e31.	0.5	6
97	Single European Currency and Monetary Union. <i>Pharmacoeconomics</i> , 1998, 13, 9-20.	3.3	5
98	Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. <i>Health Research Policy and Systems</i> , 2016, 14, 39.	2.8	5
99	The burden of colorectal cancer: prevention, treatment and quality of services. <i>European Journal of Health Economics</i> , 2010, 10, 1-3.	2.8	4
100	Prescription drug coverage among elderly and disabled Americans: can Medicare's Part D reduce inequities in access?. <i>International Journal of Health Care Finance and Economics</i> , 2010, 10, 203-218.	1.2	4
101	Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. <i>Health Policy OPEN</i> , 2021, 2, 100045.	1.5	4
102	A Prospective View on European Pharmaceutical Research and Development. <i>Pharmacoeconomics</i> , 1998, 13, 181-190.	3.3	3
103	Senior Citizens and the Burden of Prescription Drug Outlays. <i>Applied Health Economics and Health Policy</i> , 2004, 3, 217-227.	2.1	3
104	Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 15-16.	1.4	3
105	Comment on: "Does MCDA Trump CEA?". <i>Applied Health Economics and Health Policy</i> , 2019, 17, 123-124.	2.1	3
106	Acquiring Pharmaceutical Industry Assets in the UK: 1+1=1?. <i>Pharmaceutical Medicine</i> , 2014, 28, 245-248.	1.9	2
107	Clinical, Ethical, and Socioeconomic Considerations for Prescription Drug Use During Pregnancy in Women Suffering From Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 947-956.	1.6	2
108	Towards High Quality Health Care and Sustainable Financing – the Role of Health Care Programmes. <i>Global Policy</i> , 2017, 8, 46-59.	1.7	2

#	ARTICLE	IF	CITATIONS
109	Impact and Costs of Pharmaceuticals and Biotechnology. , 2016, , 107-187.		0
110	Health Care after the Great Recession: Financing Options for Sustainable and High-quality Health Systems. Global Policy, 2017, 8, 5-6.	1.7	0